Dose #9: Digital CDMOs, AI, and the Future of Pharma with Bryan Holmes (Andelyn Biosciences)

In this episode of SCW for Pharma, host Evren Ozkaya welcomes Bryan Holmes, Vice President of Information Technology at Andelyn Biosciences, to discuss the evolving role of IT in pharmaceutical manufacturing and the transformative impact of digitalization on Contract Development and Manufacturing Organizations (CDMOs). The conversation begins with a deep dive into the fundamental differences between traditional pharmaceutical manufacturing and the rapidly growing field of cell and gene therapy, a market that exceeded $5 billion in 2024 and sustains an annual growth rate of over 25%. Bryan explains how these personalized treatments, often targeted for rare diseases and small patient populations, require an entirely new approach to manufacturing, one that prioritizes agility and responsiveness. Evren and Bryan explore how IT strategy plays a pivotal role in modern pharma operations. They discuss the challenges of digital transformation, from ensuring regulatory compliance and data security to bridging communication gaps between CDMOs and their clients. Bryan highlights the ongoing shift toward data sharing, transparency, and accountability in CDMO partnerships—critical for optimizing production processes. The discussion then shifts to the cost-benefit analysis of digitalization, weighing Software-as-a-Service (SaaS) solutions against customized approaches. Evren emphasizes that while change management is difficult, companies that invest in digital transformation today will secure a long-term competitive advantage, as the pharma shop floor is poised for dramatic evolution over the next two decades. Looking ahead, Bryan and Evren explore AI's biggest opportunities in pharma. From automating routine tasks to enhancing quality assurance, AI-driven solutions are unlocking new efficiencies. Bryan underscores that the younger workforce expects technology-driven workplaces, making digitalization not just a competitive edge but a necessity for attracting top talent. Evren and Bryan wrap up their discussion with a call to action: embracing IT and digital transformation is no longer optional but essential for pharma companies looking to stay ahead in an industry evolving at an unprecedented pace.